Blue Sky Specialty Pharmacy New Partnership With UCB’s Bimzelx(R) (Bimekizumab-Bkzx)

MOUNT PLEASANT, SC / ACCESSWIRE / November 27, 2023 / Blue Sky Specialty Pharmacy, a prominent provider of comprehensive specialty pharmacy services, is proud to announce the BIMZELX Bridge Program along with UCB, Inc. for their latest groundbreaking medication Bimzelx® (bimekizumab-bkzx), which has been approved by the FDA for treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. This collaboration between Blue Sky Specialty Pharmacy and UCB brings together vital expertise, innovation, and a shared commitment to enhancing patient care.

Blue Sky Logo

Bimzelx® is a first-of-its-kind treatment currently approved for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. This medication is the only FDA approved biologic that selectively inhibits the two immune system proteins IL-17A & IL-17F which are key drivers to inflammation. This revolutionary product represents a significant advancement in dermatology and addresses critical needs within the field.

Through Blue Sky’s collaboration with the BIMZELX Bridge Program, patients will benefit from improved access to the medication, enhanced medication monitoring and coordination, streamlined access, and the superior customer service and comprehensive support that Blue Sky is known for. Both Blue Sky and UCB are excited about the potential impact of this relationship and remain vigilant in a common goal of providing exceptional care and products to improve patient healthcare journey outcomes.

For more information about the BIMZELX Bridge Program at Blue Sky Specialty Pharmacy or inquiries about our partnership, please contact Dennis Thomas, SVP of Trade and Strategic Relations at Dennis@bssprx.com. For more general questions about the BIMZELX Bridge Program please visit BIMZELX.com.

About Blue Sky Specialty Pharmacy
With locations in Mount Pleasant, SC, Daphne, AL, and Charlotte, NC, Blue Sky Specialty Pharmacy was founded with the vision to re-imagine pharmacy as we know it. Our goal is to create meaningful and enduring impact on our practices and patients and to alleviate the administrative burden and headaches associated with specialty treatments so our practices and providers can focus on treating patients.

Contact Information
Sara Glime
Marketing Director
sara@bssprx.com
843-936-7076

SOURCE: Blue Sky Specialty Pharmacy

View source version on accesswire.com:
https://www.accesswire.com/809137/blue-sky-specialty-pharmacy-new-partnership-with-ucbs-bimzelxr-bimekizumab-bkzx

Staff

Recent Posts

MindHYVE.ai™ and KPSIAJ Sign Strategic MOU to Advance AI-Driven Innovation in Education and Healthcare Across Karachi

KARACHI, Pakistan, Dec. 22, 2025 /PRNewswire/ -- MindHYVE.ai, Inc., and Khoja (Pirhai) Shia Isna Asheri Jamaat…

1 hour ago

Castle Connolly Names Dr. Meegan Gruber, MD, PhD a 2026 Exceptional Woman in Medicine; Recognition to Be Featured in New York Magazine

Board-certified plastic surgeon and surgeon-scientist honored for clinical excellence, leadership, and commitment to patient education. …

1 hour ago

Planning Time Off in 2026: Dr. Meegan Gruber, MD, PhD Releases a Recovery-Logistics Guide for Busy Professionals Considering Plastic Surgery

New "Recovery Logistics" checklist helps patients coordinate work, childcare, travel, and follow-up support-before they choose…

1 hour ago

How to Choose a Plastic Surgeon in 2026: Dr. Meegan Gruber, MD, PhD Releases a Tampa Bay Patient Safety Checklist

Board-certified plastic surgeon shares a practical, question-based guide to help patients verify credentials, facility standards,…

1 hour ago

Facelift + Eyelid Surgery in Tampa: Gruber Plastic Surgery Shares 2025 Planning Insights on Natural Results and Popular Procedure Pairings

ASPS trend reporting highlights facelift combined with eyelid surgery as a leading 2025 combination; national…

1 hour ago

CV Sciences, Inc. Positioned to Participate in the Medicare and Medicaid Pilot Program for CBD

SAN DIEGO, CA / ACCESS Newswire / December 22, 2025 / CV Sciences, Inc. (OTCQB:CVSI)…

4 hours ago